Annual Operating Profit
-$267.82 M
+$268.38 M+50.05%
31 December 2023
Summary:
Sarepta Therapeutics annual operaing income is currently -$267.82 million, with the most recent change of +$268.38 million (+50.05%) on 31 December 2023. During the last 3 years, it has risen by +$181.89 million (+40.45%). SRPT annual operating profit is now -12073.82% below its all-time high of -$2.20 million, reached on 31 December 1996.SRPT Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
$22.20 M
+$22.90 M+3266.33%
30 September 2024
Summary:
Sarepta Therapeutics quarterly operating income is currently $22.20 million, with the most recent change of +$22.90 million (+3266.33%) on 30 September 2024. Over the past year, it has dropped by -$2.43 million (-9.86%). SRPT quarterly operating profit is now -36.41% below its all-time high of $34.91 million, reached on 31 March 2024.SRPT Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
$81.03 M
+$43.04 M+113.30%
30 September 2024
Summary:
Sarepta Therapeutics TTM operating income is currently $81.03 million, with the most recent change of +$43.04 million (+113.30%) on 30 September 2024. Over the past year, it has increased by +$348.85 million (+130.25%). SRPT TTM operating profit is now at all-time high.SRPT TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -9.9% | +130.3% |
| 3 y3 years | +40.5% | +121.0% | +118.0% |
| 5 y5 years | +48.7% | +110.1% | +115.5% |
SRPT Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +50.0% | -36.4% | +110.5% | at high | +113.8% |
| 5 y | 5 years | at high | +52.5% | -36.4% | +110.1% | at high | +113.1% |
| alltime | all time | <-9999.0% | +52.5% | -36.4% | +110.1% | at high | +113.1% |
Sarepta Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $22.20 M(-3266.3%) | $81.03 M(+113.3%) |
| June 2024 | - | -$701.00 K(-102.0%) | $37.99 M(-140.1%) |
| Mar 2024 | - | $34.91 M(+41.7%) | -$94.83 M(-64.6%) |
| Dec 2023 | -$267.82 M(-50.1%) | $24.63 M(-218.2%) | -$267.82 M(-32.9%) |
| Sept 2023 | - | -$20.84 M(-84.4%) | -$399.28 M(-21.7%) |
| June 2023 | - | -$133.52 M(-3.3%) | -$509.80 M(-13.2%) |
| Mar 2023 | - | -$138.09 M(+29.3%) | -$587.41 M(+9.5%) |
| Dec 2022 | -$536.20 M(+19.2%) | -$106.83 M(-18.7%) | -$536.20 M(+0.2%) |
| Sept 2022 | - | -$131.35 M(-37.8%) | -$535.18 M(+22.1%) |
| June 2022 | - | -$211.13 M(+143.0%) | -$438.28 M(+11.0%) |
| Mar 2022 | - | -$86.88 M(-17.9%) | -$394.73 M(-12.2%) |
| Dec 2021 | -$449.71 M(-20.3%) | -$105.81 M(+207.1%) | -$449.71 M(-12.6%) |
| Sept 2021 | - | -$34.46 M(-79.4%) | -$514.61 M(-16.6%) |
| June 2021 | - | -$167.57 M(+18.1%) | -$617.22 M(+5.0%) |
| Mar 2021 | - | -$141.87 M(-16.9%) | -$588.00 M(+4.2%) |
| Dec 2020 | -$564.16 M(+8.0%) | -$170.72 M(+24.5%) | -$564.16 M(-8.1%) |
| Sept 2020 | - | -$137.07 M(-0.9%) | -$613.67 M(+2.2%) |
| June 2020 | - | -$138.35 M(+17.2%) | -$600.19 M(+6.4%) |
| Mar 2020 | - | -$118.03 M(-46.4%) | -$563.96 M(+8.0%) |
| Dec 2019 | -$522.32 M(+52.0%) | -$220.22 M(+78.2%) | -$522.32 M(+18.9%) |
| Sept 2019 | - | -$123.59 M(+21.0%) | -$439.25 M(+13.9%) |
| June 2019 | - | -$102.13 M(+33.7%) | -$385.75 M(-0.9%) |
| Mar 2019 | - | -$76.39 M(-44.3%) | -$389.28 M(+13.3%) |
| Dec 2018 | -$343.63 M(+139.9%) | -$137.14 M(+95.6%) | -$343.63 M(+48.0%) |
| Sept 2018 | - | -$70.10 M(-33.6%) | -$232.22 M(+27.3%) |
| June 2018 | - | -$105.65 M(+243.7%) | -$182.44 M(+35.3%) |
| Mar 2018 | - | -$30.74 M(+19.4%) | -$134.87 M(-5.9%) |
| Dec 2017 | -$143.21 M(-45.8%) | -$25.74 M(+26.7%) | -$143.38 M(-29.8%) |
| Sept 2017 | - | -$20.32 M(-65.0%) | -$204.13 M(-15.1%) |
| June 2017 | - | -$58.08 M(+48.0%) | -$240.34 M(-1.6%) |
| Mar 2017 | - | -$39.24 M(-54.6%) | -$244.25 M(-7.7%) |
| Dec 2016 | -$264.18 M(+20.0%) | -$86.49 M(+53.0%) | -$264.71 M(+9.1%) |
| Sept 2016 | - | -$56.53 M(-8.8%) | -$242.67 M(+2.0%) |
| June 2016 | - | -$61.98 M(+3.8%) | -$237.90 M(+9.1%) |
| Mar 2016 | - | -$59.70 M(-7.4%) | -$218.02 M(-1.0%) |
| Dec 2015 | -$220.18 M(+64.6%) | -$64.45 M(+24.5%) | -$220.18 M(+9.8%) |
| Sept 2015 | - | -$51.76 M(+22.9%) | -$200.45 M(+9.9%) |
| June 2015 | - | -$42.11 M(-31.9%) | -$182.37 M(+6.9%) |
| Mar 2015 | - | -$61.86 M(+38.3%) | -$170.53 M(+27.5%) |
| Dec 2014 | -$133.79 M(+48.2%) | -$44.72 M(+32.8%) | -$133.79 M(+9.7%) |
| Sept 2014 | - | -$33.67 M(+11.2%) | -$121.92 M(+7.7%) |
| June 2014 | - | -$30.27 M(+20.5%) | -$113.17 M(+13.2%) |
| Mar 2014 | - | -$25.12 M(-23.5%) | -$99.99 M(+10.8%) |
| Dec 2013 | -$90.28 M(+204.0%) | -$32.85 M(+31.7%) | -$90.28 M(+33.2%) |
| Sept 2013 | - | -$24.93 M(+45.9%) | -$67.80 M(+36.2%) |
| June 2013 | - | -$17.09 M(+10.8%) | -$49.77 M(+30.1%) |
| Mar 2013 | - | -$15.41 M(+48.7%) | -$38.24 M(+28.8%) |
| Dec 2012 | -$29.70 M(-17.3%) | -$10.37 M(+50.1%) | -$29.70 M(+4.8%) |
| Sept 2012 | - | -$6.91 M(+24.3%) | -$28.34 M(-13.4%) |
| June 2012 | - | -$5.56 M(-19.2%) | -$32.70 M(-12.3%) |
| Mar 2012 | - | -$6.87 M(-23.6%) | -$37.27 M(+3.7%) |
| Dec 2011 | -$35.93 M(+71.6%) | -$9.00 M(-20.1%) | -$35.93 M(+25.3%) |
| Sept 2011 | - | -$11.27 M(+11.3%) | -$28.67 M(+35.3%) |
| June 2011 | - | -$10.13 M(+83.1%) | -$21.19 M(+13.1%) |
| Mar 2011 | - | -$5.53 M(+217.9%) | -$18.73 M(-10.5%) |
| Dec 2010 | -$20.93 M | -$1.74 M(-54.2%) | -$20.94 M(-9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$3.80 M(-50.5%) | -$23.16 M(+3.9%) |
| June 2010 | - | -$7.67 M(-0.9%) | -$22.28 M(+13.2%) |
| Mar 2010 | - | -$7.74 M(+95.4%) | -$19.68 M(+26.9%) |
| Dec 2009 | -$15.51 M(-11.6%) | -$3.96 M(+35.6%) | -$15.51 M(+7.4%) |
| Sept 2009 | - | -$2.92 M(-42.3%) | -$14.44 M(-17.3%) |
| June 2009 | - | -$5.07 M(+42.1%) | -$17.46 M(+1.1%) |
| Mar 2009 | - | -$3.56 M(+23.2%) | -$17.28 M(-1.5%) |
| Dec 2008 | -$17.54 M(-47.0%) | -$2.89 M(-51.3%) | -$17.54 M(-13.7%) |
| Sept 2008 | - | -$5.94 M(+21.7%) | -$20.32 M(-11.3%) |
| June 2008 | - | -$4.88 M(+27.4%) | -$22.89 M(-14.8%) |
| Mar 2008 | - | -$3.83 M(-32.4%) | -$26.85 M(-18.9%) |
| Dec 2007 | -$33.11 M(+0.4%) | -$5.67 M(-33.4%) | -$33.11 M(-8.6%) |
| Sept 2007 | - | -$8.51 M(-3.7%) | -$36.21 M(+3.5%) |
| June 2007 | - | -$8.84 M(-12.3%) | -$34.97 M(+4.2%) |
| Mar 2007 | - | -$10.09 M(+15.0%) | -$33.55 M(+1.7%) |
| Dec 2006 | -$32.98 M(+88.3%) | -$8.77 M(+20.6%) | -$32.98 M(+13.3%) |
| Sept 2006 | - | -$7.27 M(-2.0%) | -$29.12 M(+22.5%) |
| June 2006 | - | -$7.42 M(-22.1%) | -$23.76 M(+10.6%) |
| Mar 2006 | - | -$9.52 M(+94.1%) | -$21.49 M(+22.7%) |
| Dec 2005 | -$17.52 M(-30.1%) | -$4.91 M(+155.8%) | -$17.52 M(-0.2%) |
| Sept 2005 | - | -$1.92 M(-62.8%) | -$17.55 M(-15.4%) |
| June 2005 | - | -$5.15 M(-7.2%) | -$20.75 M(-9.1%) |
| Mar 2005 | - | -$5.55 M(+12.3%) | -$22.84 M(-8.8%) |
| Dec 2004 | -$25.04 M(+32.7%) | -$4.94 M(-3.6%) | -$25.04 M(-8.1%) |
| Sept 2004 | - | -$5.12 M(-29.2%) | -$27.27 M(+1.7%) |
| June 2004 | - | -$7.23 M(-6.7%) | -$26.82 M(+15.9%) |
| Mar 2004 | - | -$7.75 M(+8.3%) | -$23.14 M(+22.6%) |
| Dec 2003 | -$18.87 M(-25.5%) | -$7.16 M(+53.0%) | -$18.87 M(+18.9%) |
| Sept 2003 | - | -$4.68 M(+31.7%) | -$15.87 M(-4.2%) |
| June 2003 | - | -$3.55 M(+2.1%) | -$16.56 M(-20.9%) |
| Mar 2003 | - | -$3.48 M(-16.1%) | -$20.93 M(-17.4%) |
| Dec 2002 | -$25.34 M(+64.5%) | -$4.15 M(-22.7%) | -$25.34 M(-2.2%) |
| Sept 2002 | - | -$5.37 M(-32.2%) | -$25.92 M(+8.5%) |
| June 2002 | - | -$7.92 M(+0.3%) | -$23.89 M(+20.9%) |
| Mar 2002 | - | -$7.90 M(+66.9%) | -$19.76 M(+28.3%) |
| Dec 2001 | -$15.40 M(+50.4%) | -$4.73 M(+41.5%) | -$15.40 M(+9.1%) |
| Sept 2001 | - | -$3.35 M(-11.6%) | -$14.12 M(+5.6%) |
| June 2001 | - | -$3.78 M(+6.9%) | -$13.37 M(+6.6%) |
| Mar 2001 | - | -$3.54 M(+2.5%) | -$12.54 M(+22.5%) |
| Dec 2000 | -$10.24 M(+23.4%) | -$3.45 M(+33.3%) | -$10.24 M(+12.7%) |
| Sept 2000 | - | -$2.59 M(-12.3%) | -$9.09 M(+4.5%) |
| June 2000 | - | -$2.96 M(+138.2%) | -$8.70 M(+13.8%) |
| Mar 2000 | - | -$1.24 M(-46.1%) | -$7.64 M(-4.5%) |
| Dec 1999 | -$8.30 M(+6.4%) | -$2.30 M(+4.5%) | -$8.00 M(-3.6%) |
| Sept 1999 | - | -$2.20 M(+15.8%) | -$8.30 M(+5.1%) |
| June 1999 | - | -$1.90 M(+18.8%) | -$7.90 M(+2.6%) |
| Mar 1999 | - | -$1.60 M(-38.5%) | -$7.70 M(+1.3%) |
| Dec 1998 | -$7.80 M(+100.0%) | -$2.60 M(+44.4%) | -$7.60 M(+26.7%) |
| Sept 1998 | - | -$1.80 M(+5.9%) | -$6.00 M(+17.6%) |
| June 1998 | - | -$1.70 M(+13.3%) | -$5.10 M(+10.9%) |
| Mar 1998 | - | -$1.50 M(+50.0%) | -$4.60 M(+24.3%) |
| Dec 1997 | -$3.90 M(+77.3%) | -$1.00 M(+11.1%) | -$3.70 M(+37.0%) |
| Sept 1997 | - | -$900.00 K(-25.0%) | -$2.70 M(+50.0%) |
| June 1997 | - | -$1.20 M(+100.0%) | -$1.80 M(+200.0%) |
| Mar 1997 | - | -$600.00 K | -$600.00 K |
| Dec 1996 | -$2.20 M | - | - |
FAQ
- What is Sarepta Therapeutics annual operaing income?
- What is the all time high annual operating profit for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly operating profit year-on-year change?
- What is Sarepta Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM operating profit year-on-year change?
What is Sarepta Therapeutics annual operaing income?
The current annual operating profit of SRPT is -$267.82 M
What is the all time high annual operating profit for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual operaing income is -$2.20 M
What is Sarepta Therapeutics quarterly operating income?
The current quarterly operating profit of SRPT is $22.20 M
What is the all time high quarterly operating profit for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly operating income is $34.91 M
What is Sarepta Therapeutics quarterly operating profit year-on-year change?
Over the past year, SRPT quarterly operating income has changed by -$2.43 M (-9.86%)
What is Sarepta Therapeutics TTM operating income?
The current TTM operating profit of SRPT is $81.03 M
What is the all time high TTM operating profit for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM operating income is $81.03 M
What is Sarepta Therapeutics TTM operating profit year-on-year change?
Over the past year, SRPT TTM operating income has changed by +$348.85 M (+130.25%)